CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars:  On January 30, 2025, the European Medicines Agency (EMA) Committee ...

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast ...

AAM said that by including drugs with generics and biosimilars in development in the 15 drugs selected for negotiation, CMS ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...